Overview of PD-1/PD-L1 inhibitors, mechanisms of action, trial designations and approved companion diagnostics
| Agent | Mechanism of action | Trial name(s) | FDA-approved PD-L1 companion diagnostic |
|---|---|---|---|
| Pembrolizumab | PD-1 inhibitor | KEYNOTE | Primary antibody: 22C3 (Dako)IHC scoring: Tumor cell membraneTherapeutic developer: Merck |
| Nivolumab | PD-1 inhibitor | CheckMate | Primary antibody: 28-8 (Dako)IHC scoring: Tumor cell membraneTherapeutic developer: BMS |
| Atezolizumab | PD-L1 inhibitor | IMVigor (UC), POPLAR (NSCLC), OAK (NSCLC) | Primary antibody: SP142 (Ventana)IHC scoring: Tumor cell membrane, infiltrating immune cellsTherapeutic developer: Genentech |
| Durvalumab | PD-L1 inhibitor | Study 1108 | Primary antibody: SP263 (Ventana)IHC scoring: Tumor cell membraneTherapeutic developer: AstraZeneca |
| Avelumab | PD-L1 inhibitor | JAVELIN | Primary antibody: 73-10 (Dako)aIHC scoring: Tumor cell membraneTherapeutic developer: Merck, Pfizer |
PD-1 programmed cell death 1, PD-L1 programmed death ligand 1, FDA Food and Drug Administration, IHC immunohistochemistry, BMS Bristol-Myers Squibb, UC urothelial carcinoma, NSCLC non-small cell lung cancer
a For research use only